MAPS publishes a free open-access ibogaine Investigator's Brochure to support researchers with pharmacology, safety, dosing, and clinical development guidance

Ibogaine research gains a new open-access reference with MAPS publishing an Investigator's Brochure for scientists, clinicians, regulators, and study teams working on clinical development. The resource centers on core evidence needed to evaluate ibogaine in research settings, including pharmacology, safety considerations, dosing information, and the current state of development. Clinical interest in ibogaine has grown because of its potential relevance to substance use and mental health treatment, while safety concerns - especially cardiac and medical risks - have limited wider adoption and increased the need for rigorous protocols. A publicly available brochure can help standardize background knowledge across institutions and lower access barriers for early-stage investigators. Open scientific materials like this matter because ibogaine remains promising but highly complex. Better shared documentation can improve trial design, ethical review, and risk management while supporting more transparent evaluation of benefits, limitations, and next steps for the field.